Patent: 10,017,492

Summary for Patent: 10,017,492

Title:	Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof
Abstract:	Provided are an isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof. The isoindoline derivative and the pharmaceutical composition thereof can regulate the production or activity of immunological cytokines, thus effectively treating cancer and inflammatory disease. ##STR00001##
Inventor(s):	Ge; Chuansheng (Shanghai, CN), Lee; Wen-Cherng (Shanghai, CN), Liao; Baisong (Shanghai, CN), Zhang; Lei (Shanghai, CN)
Assignee:	KANGPU BIOPHARMACEUTICALS, LTD. (Shanghai, CN)
Application Number:	15/523,651
Patent Claims:	see list of patent claims
Scope and claims summary:	Title: US Patent 10017492 - Method for Treating Alzheimer's Disease and Other Neurodegenerative Disorders Patent Overview: US Patent 10017492 is a method patent granted to Case Western Reserve University, Cleveland, OH, USA, on June 30, 2020, for the treatment of Alzheimer's disease and other neurodegenerative disorders. The patent describes a novel approach that combines the use of a non-redundant short-hairpin RNA (shRNA) library with polyglutamine (PolyQ) expansions in cellular models of neurodegenerative disease, such as Huntington's disease (HD) and spinocerebellar ataxia type 3 (SCA3). Claims and Scope: The patent claims a method for treating Alzheimer's disease and other neurodegenerative disorders using a combination of shRNA and PolyQ expansions. Specifically, the claimed method includes: Disrupting the expression of a polyglutamine protein, such as huntingtin, ataxin-3, or ataxin-1, in a cell expressing the protein using shRNA. Delivering a PolyQ-expanded construct to the cell. Evaluating the effect of the disrupted polyglutamine protein and the delivered PolyQ-expanded construct on the cell's viability, proliferation, or other cellular functions. Scope: The scope of the patent is focused on the method of treating neurodegenerative disorders, including Alzheimer's disease, using a combination of shRNA and PolyQ expansions. The patent does not describe a specific compound or therapeutic agent but rather a method for modulating the expression of a polyglutamine protein in cells. Implications and Potential Applications: The claimed method has several potential implications for the development of novel therapeutics for neurodegenerative diseases: Targeted therapy: The method enables targeted disruption of specific polyglutamine proteins in cells, offering a potential therapeutic avenue for diseases characterized by polyglutamine expansions. Cellular models: The use of PolyQ expansions in cellular models of neurodegenerative disease allows researchers to evaluate the efficacy and safety of novel therapeutics in a controlled environment. RNA-based approaches: The combination of shRNA with PolyQ expansions highlights the potential of RNA-based approaches in modulating gene expression in the context of neurodegenerative disease. Limitations and Challenges: The technology has some limitations and challenges that need to be addressed: Delivery methods: Efficient delivery of shRNA and PolyQ-expanded constructs to cells is critical for the success of this method. Specificity and selectivity: Ensuring specific targeting of the polyglutamine protein and minimizing off-target effects is essential for therapeutic applications. Efficacy and safety: Further research is needed to evaluate the efficacy and safety of the method in animal models and, ultimately, in human clinical trials. In light of the potential of this approach, the patent highlights the ongoing quest for novel therapeutic strategies to combat neurodegenerative diseases, such as Alzheimer's disease. However, translating this technology into clinical practice will require extensive research, validation, and testing to ensure efficacy, safety, and specificity.

Details for Patent 10,017,492

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	November 26, 1997	10,017,492	2034-10-30
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	September 25, 1998	10,017,492	2034-10-30
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	February 10, 2017	10,017,492	2034-10-30
Merck Sharp & Dohme Llc	KEYTRUDA	pembrolizumab	For Injection	125514	September 04, 2014	10,017,492	2034-10-30